Agrup G, Björnberg A, Elmros T, Groth O, Hannuksela M, Lassus A, Salde L, Skogh M, Thomsen K
Acta Derm Venereol. 1981;61(2):180-2.
In a double-blind, randomized multi-centre study, 116 patients with psoriasis have been treated for 1-3 weeks with budesonide ointment (Preferid, Draco/Tika; a subsidiary of AB ASTRA), a new non-halogenated topical steroid. In a series of 11 patients a 0.025% budesonide ointment was significantly superior to placebo. In a second series, of 54 patients, a 0.025% fluocinolone acetonide ointment (Synalar, ICI). In a third series, of 51 patients, a 0.010% budesonide ointment was compared with 0.025% fluocinolone acetonide ointment. No statistically significant difference between these two preparations was found to exist. No adverse reactions were observed.
在一项双盲、随机多中心研究中，116例银屑病患者接受了新型非卤化外用类固醇布地奈德软膏（普倍他索，德科/蒂卡；阿斯特拉公司子公司）治疗1至3周。在一组11例患者中，0.025%布地奈德软膏显著优于安慰剂。在第二组54例患者中，使用的是0.025%醋酸氟轻松软膏（仙乃乐，帝国化学工业公司）。在第三组51例患者中，将0.010%布地奈德软膏与0.025%醋酸氟轻松软膏进行了比较。发现这两种制剂之间不存在统计学上的显著差异。未观察到不良反应。
